Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q3 Revenues Jump 26 Percent as Net Loss Declines 30 Percent

NEW YORK (GenomeWeb News) — Third Wave Technologies today said third-quarter revenues increases 26 percent as net loss declined 30 percent.
 
Total receipts for the three months ended Sept. 30 increased to $6.6 million from $5.2 million year over year. Molecular diagnosis contributed $5.2 million.
 
R&D expenses on the quarter were up sharply, at $3.5 million compared with $2 million the previous year.
 
Quarterly losses slid 30 percent in the period to $5.2 million from $7.4 million year over year.
 
At the end of the quarter Third Wave had around $33 million in cash, cash equivalents, and short-term investments.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.